These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 17551391)

  • 21. Should we be using intraarticular tumor necrosis factor blockade in inflammatory monoarthritis?
    Fisher BA; Keat A
    J Rheumatol; 2006 Oct; 33(10):1934-5. PubMed ID: 17014012
    [No Abstract]   [Full Text] [Related]  

  • 22. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.
    Burmester GR; Mariette X; Montecucco C; Monteagudo-Sáez I; Malaise M; Tzioufas AG; Bijlsma JW; Unnebrink K; Kary S; Kupper H
    Ann Rheum Dis; 2007 Jun; 66(6):732-9. PubMed ID: 17329305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
    Tanaka T; Kuwahara Y; Shima Y; Hirano T; Kawai M; Ogawa M; Arimitsu J; Hagihara K; Narazaki M; Ogata A; Kawase I; Kishimoto T
    Arthritis Rheum; 2009 Dec; 61(12):1762-4. PubMed ID: 19950316
    [No Abstract]   [Full Text] [Related]  

  • 24. New drugs for rheumatoid arthritis.
    Messori A; Santarlasci B; Vaiani M
    N Engl J Med; 2004 Aug; 351(9):937-8. PubMed ID: 15329436
    [No Abstract]   [Full Text] [Related]  

  • 25. Alopecia areata universalis elicited during treatment with adalimumab.
    Pelivani N; Hassan AS; Braathen LR; Hunger RE; Yawalkar N
    Dermatology; 2008; 216(4):320-3. PubMed ID: 18230980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-tumor necrosis factor-alpha agents for rheumatoid arthritis: assessing longterm safety.
    Hyrich KL; Silman AJ
    J Rheumatol; 2006 May; 33(5):831-3. PubMed ID: 16652412
    [No Abstract]   [Full Text] [Related]  

  • 27. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation.
    de Vries MK; Brouwer E; van der Horst-Bruinsma IE; Spoorenberg A; van Denderen JC; Jamnitski A; Nurmohamed MT; Dijkmans BA; Aarden LA; Wolbink GJ
    Ann Rheum Dis; 2009 Nov; 68(11):1787-8. PubMed ID: 19822712
    [No Abstract]   [Full Text] [Related]  

  • 28. [Pharmacotherapy of rheumatoid arthritis in the era of genetically engineered biological preparations].
    Nasonov EL
    Ter Arkh; 2007; 79(5):5-8. PubMed ID: 17672066
    [No Abstract]   [Full Text] [Related]  

  • 29. TNF blocker drugs used to fight inflammation go head-to-head. Adalimumab had highest treatment response and remission rates, etanercept has longest drug survival rates; infliximab placed third.
    Duke Med Health News; 2010 Mar; 16(3):3. PubMed ID: 20461880
    [No Abstract]   [Full Text] [Related]  

  • 30. Permanent renal loss following tumor necrosis factor α antagonists for arthritis.
    Chen TJ; Yang YF; Huang PH; Lin HH; Huang CC
    Rheumatol Int; 2010 Jun; 30(8):1077-9. PubMed ID: 19536543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spectacular evolution of reactive arthritis after early treatment with infliximab.
    Thomas-Pohl M; Tissot A; Banal F; Lechevalier D
    Joint Bone Spine; 2012 Oct; 79(5):524. PubMed ID: 22542050
    [No Abstract]   [Full Text] [Related]  

  • 32. Psoriasiform lesions induced by tumour necrosis factor antagonists: a skin-deep medical conundrum.
    Carter JD; Gerard HC; Hudson AP
    Ann Rheum Dis; 2008 Aug; 67(8):1181-3. PubMed ID: 18299302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-TNF-alpha therapies: they are all the same (aren't they?).
    Mpofu S; Fatima F; Moots RJ
    Rheumatology (Oxford); 2005 Mar; 44(3):271-3. PubMed ID: 15561736
    [No Abstract]   [Full Text] [Related]  

  • 34. Case records of the Massachusetts General Hospital. Case 13-2009. A 54-year-old woman with respiratory failure and a cavitary lesion in the lung.
    Weinblatt ME; Abbott GF; Koreishi AF
    N Engl J Med; 2009 Apr; 360(17):1770-9. PubMed ID: 19387019
    [No Abstract]   [Full Text] [Related]  

  • 35. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001).
    Ledingham J; Deighton C;
    Rheumatology (Oxford); 2005 Feb; 44(2):157-63. PubMed ID: 15637039
    [No Abstract]   [Full Text] [Related]  

  • 36. Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge.
    van der Stoep D; Braunstahl GJ; van Zeben J; Wouters J
    J Rheumatol; 2009 Dec; 36(12):2847-8. PubMed ID: 19966199
    [No Abstract]   [Full Text] [Related]  

  • 37. Successful treatment of refractory rheumatoid arthritis-associated leg ulcerations with adalimumab.
    Hirche D; Rubbert A; Lunau L; Krieg T; Eming SA
    Br J Dermatol; 2005 May; 152(5):1062-4. PubMed ID: 15888173
    [No Abstract]   [Full Text] [Related]  

  • 38. [Fully human anti TNF-alpha monoclonal antibodies (adalimumab, golimumab)].
    Hirohata S
    Nihon Rinsho; 2007 Jul; 65(7):1202-8. PubMed ID: 17642233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severe polymyositis and flare in autoimmunity following treatment with adalimumab in a patient with overlapping features of polyarthritis and scleroderma.
    Liozon E; Ouattara B; Loustaud-Ratti V; Vidal E
    Scand J Rheumatol; 2007; 36(6):484-6. PubMed ID: 18092275
    [No Abstract]   [Full Text] [Related]  

  • 40. Saline breast implant fluid collection and reactive arthritis in a patient with streptococcal toxic shock syndrome.
    Kohannim O; Rubin Z; Taylor M
    J Clin Rheumatol; 2011 Mar; 17(2):89-91. PubMed ID: 21325958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.